Search the Newsreel

Coherus Oncology Q2 2026 Earnings: LOQTORZI Growth Narrows the Loss

Coherus Oncology reported fiscal Q2 2026 net revenue of $14.3 million, a 40% increase year-over-year, driven primarily by LOQTORZI sales. The company narrowed its diluted loss per share to $0.22, largely due to LOQTORZI volume growth and reduced operating expenses. However, net cash used …

Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue

Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates

Coherus Oncology (CHRS) Earnings Date and Reports 2026

Coherus BioSciences earnings beat by $0.07, revenue fell short of estimates

Coherus BioSciences Inc (CHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Coherus BioSciences Inc (CHRS), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 2.69, ranking 118 out of 156 in the Pharmaceuticals industry, with a beta of 0.99 indicating underperformance in upward …

Coherus BioSciences Inc (CHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Coherus BioSciences Inc (CHRS), detailing its price momentum score of 4.09 and its position within the Pharmaceuticals industry. It identifies key support and resistance levels for the stock, indicating suitability for range-bound swing trading. The analysis also …

Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 7.59 within the Pharmaceuticals industry. The company's P/E ratio is 0.86, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, …

Coherus BioSciences Inc (CHRS) Institutional Confidence

Coherus BioSciences Inc (CHRS) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 35.13%, marking a significant quarter-over-quarter decrease of 49.78%. James Simons is listed as the largest institutional shareholder, holding …

Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed

A recent Lobbying Disclosure Act filing revealed that COHERUS BIOSCIENCES INC. engaged in $95,000 worth of lobbying during Q2 2026. The lobbying efforts focused on issues like oncology, Medicare coverage, domestic drug production, and supply chain security. Additionally, the article highlights recent hedge fund …

Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings

The article provides a detailed breakdown of Coherus BioSciences Inc.'s (CHRS) shareholder structure, listing major individual and institutional holders. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and shows trends in institutional shareholding and activity over several quarters. Finally, it lists …

Coherus BioSciences Inc (CHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Coherus BioSciences Inc (CHRS) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and lists basic market data such as market capitalization and …

Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), segmenting its income by business product and geographic region as of April 6. The data shows that UDENYCA is the primary revenue driver, contributing 99.24% of the reported revenue, with the United …

Coherus BioSciences Inc (CHRS) Financial Health: Profitability & Balance Sheet Analysis

Coherus BioSciences Inc (CHRS) currently holds a financial score of 6.23, ranking 143 out of 155 in the Pharmaceuticals industry, indicating stable financial health but low operating efficiency. The company recently reported a quarterly revenue of $12.31M, marking a 61.99% year-over-year increase, and a …

CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020

Coherus BioSciences Inc (CHRS) shows relatively healthy fundamentals and high growth potential, though its stock price is expected to trend down in the medium term. The company's valuation is considered fair, ranking 97 out of 155 in the Pharmaceuticals industry, with strong institutional ownership. …

Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook

Coherus BioSciences (CHRS) stock is trading lower due to declining revenue from its biosimilar Udenyca and a challenging market. The company reported a significant revenue drop in 2023 and Q1 2024, alongside ongoing net losses, though Q1 2024 showed some narrowing of losses. Coherus …

Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues

Coherus BioSciences (CHRS) stock is trading near recent lows due to declining biosimilar revenue and a strategic pivot towards oncology. The company reported a significant drop in fiscal 2023 revenue and widening net losses, reflecting intense competition in its legacy biosimilar products. Despite the …